Skip to main content

Find Clinical Trials

Home
Conditions
Refractory Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma

Clinical trial condition

Refractory Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma

Explore clinical trials studying Refractory Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma. Study availability and eligibility vary by location and protocol.

1 public trial 0 recruiting studies

Refine in advanced search Browse all conditions

Refractory Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma trial results

Not Yet Recruiting

Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma

NCT07691450

Conditions: Enteropathy-Associated T-Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +36 more
Locations: City of Hope Medical Center Duarte, California, United States

View Trial Details